Aschauer Julia, Donner Ruth, Lammer Jan, Schmidinger Gerald
Department of Ophthalmology and Optometry, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Am J Ophthalmol Case Rep. 2022 Mar 16;26:101489. doi: 10.1016/j.ajoc.2022.101489. eCollection 2022 Jun.
To describe a case of an immune-related adverse event associated with Atezolizumab therapy which was aggravated by ocular surgery.
A 59-year-old man treated with Atezolizumab for metastatic non-small-cell lung cancer developed a conjunctival hypertrophic lesion mistaken for metastatic tissue. Biopsy surgery induced fulminant and multifocal granulomatous conjunctival tissue growth and sterile corneal ulceration. The immune-related adverse event was refractory to topical therapy, with curative success only after introduction of systemic prednisone.
Atezolizumab use may be associated with severe and recalcitrant ocular surface inflammation with potential exacerbation after surgical interventions.
描述一例与阿替利珠单抗治疗相关的免疫相关不良事件，该事件因眼科手术而加重。
一名59岁男性因转移性非小细胞肺癌接受阿替利珠单抗治疗，出现了被误诊为转移组织的结膜肥厚性病变。活检手术引发了暴发性多灶性肉芽肿性结膜组织生长和无菌性角膜溃疡。该免疫相关不良事件局部治疗无效，仅在引入全身性泼尼松后才取得治愈成功。
使用阿替利珠单抗可能会导致严重且顽固的眼表炎症，手术干预后可能会加重。
